Bedaquiline
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Bedaquiline and local guidelines before prescribing.
Antimycobacterial
Mechanism
Diarylquinoline inhibiting mycobacterial ATP synthase.
Uses
Multidrug-resistant tuberculosis.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
QT prolongation, nausea, arthralgia, raised transaminases.
Interactions
QT-prolonging drugs, CYP3A4 inducers.
Contraindications and cautions
QT prolongation
Monitoring
ECG, LFT
Pregnancy and breastfeeding
Specialist advice
Renal and hepatic impairment
Caution in severe renal impairment
Overdose and reversal
Supportive
Special advice
ECG monitoring throughout.
More from the textbook: uses, cautions and other points
- Side effects: QT prolongation (bedaquiline, moxifloxacin), and myelosuppression and neuropathy (linezolid).
Respiratory: Infections - All-oral regimens built around newer drugs - bedaquiline , pretomanid and linezolid (with or without moxifloxacin) for 6 months (the "BPaL(M)" regimen) in many cases, or longer individualised regimens.
Respiratory: Infections - Bedaquiline, pretomanid, linezolid | MDR-TB regimens (specialist); QT prolongation, myelosuppression, neuropathy.
Respiratory: Infections - Multidrug-resistant TB (resistant to rifampicin and isoniazid) - specialist regimens (e.g. BPaLM: bedaquiline, pretomanid, linezolid ± moxifloxacin).
Microbiology: Bacteriology - structure, classification and important pathogens
Where it is discussed in the book
- Respiratory: Infections (3 mentions)
- Integrated respiratory chapter (3 mentions)
- Microbiology: Bacteriology - structure, classification and important pathogens (1 mention)